查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386506

原發性免疫力缺乏治療市場報告：2030 年趨勢、預測與競爭分析

Primary Immunodeficiency Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

原發性免疫力缺乏治療的趨勢和預測

至2030年，全球原發性免疫力缺乏治療市場預計將達到111億美元，2024年至2030年的年複合成長率為6.3%。該市場的主要驅動力是人們對原發性免疫力缺乏疾病的認知不斷提高、基因組研究的活性化以及基因檢測、流式細胞儀和次世代定序診斷技術的不斷進步。全球原發性免疫力缺乏治療市場前景廣闊，免疫球蛋白替代治療、幹細胞/骨髓移植、抗生素治療、基因治療市場都有機會。

原發性免疫力缺乏治療市場洞察

Lucintel 預測，由於人們對該疾病的認知不斷增強，而且高齡化使其更容易受到抗體缺乏的影響，抗體缺乏仍將是最大的部分。

在這個市場中，免疫球蛋白替代療法預計仍將是最大的部分，因為它有助於改善免疫系統功能並降低原發性免疫力缺乏缺陷疾病患者的感染疾病風險。

由於原發性免疫力缺乏疾病的高盛行率以及原發性免疫力缺乏治療的報銷，北美將繼續成為最大的市場。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2. 哪個產業將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和業務風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.這個市場有哪些競爭產品？此外，由於疾病類型或替代品而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球原發性免疫力缺乏治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球原發性免疫力缺乏治療市場趨勢（2018-2023）和預測（2024-2030）
  • 按類型分類的全球原發性免疫力缺乏治療市場
    • 免疫球蛋白替代療法
    • 幹細胞/骨髓移植
    • 抗生素治療
    • 基因治療
    • 其他
  • 按疾病類型分類的全球原發性免疫力缺乏治療市場
    • 抗體缺乏
    • 細胞免疫力缺乏
    • 先天性免疫疾病
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球原發性免疫力缺乏治療市場（按地區）
  • 北美原發性免疫力缺乏治療市場
  • 歐洲原發性免疫力缺乏治療市場
  • 亞太地區原發性免疫力缺乏治療市場
  • 其他區域原發性免疫力缺乏治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球原發性免疫力缺乏治療市場成長機會（按類型）
    • 按疾病類型分類的全球原發性免疫力缺乏治療市場成長機會
    • 按地區分類的全球原發性免疫力缺乏治療市場成長機會
  • 全球原發性免疫力缺乏治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球原發性免疫力缺乏治療市場的產能
    • 全球原發性免疫力缺乏治療市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Pfizer
  • CSL Behring
  • Grifols
  • Abbott
  • ADMA Biologics
  • AstraZeneca
  • Baxter
  • Bayer
  • Biocon
  • Bristol-Myers Squibb
簡介目錄

Primary Immunodeficiency Therapeutics Trends and Forecast

The future of the global primary immunodeficiency therapeutics market looks promising with opportunities in the immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, and gene therapy markets. The global primary immunodeficiency therapeutics market is expected to reach an estimated $11.1 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are increasing primary immunodeficiency disorders awareness, rising genomic research, and on-going advancement in diagnostoc technologies, such as genetic testing, flow cytometry, and next-generation sequencing.

A more than 150-page report is developed to help in your business decisions.

Primary Immunodeficiency Therapeutics by Segment

The study includes a forecast for the global primary immunodeficiency therapeutics by type, disease type, and region.

Primary Immunodeficiency Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Immunoglobulin Replacement Therapy
  • Stem Cell/Bone Marrow Transplantation
  • Antibiotic Therapy
  • Gene Therapy
  • Others

Primary Immunodeficiency Therapeutics Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

  • Antibody Deficiency
  • Cellular Immunodeficiency
  • Innate Immune Disorders
  • Others

Primary Immunodeficiency Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Primary Immunodeficiency Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies primary immunodeficiency therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the primary immunodeficiency therapeutics companies profiled in this report include-

  • Pfizer
  • CSL Behring
  • Grifols
  • Abbott
  • Adma Biologics
  • Astrazeneca
  • Baxter
  • Bayer
  • Biocon
  • Bristol-Myers Squibb

Primary Immunodeficiency Therapeutics Market Insights

Lucintel forecasts that antibody deficiency will remain the largest segment due to increasing awareness of antibody deficiency and aging population is more susceptible to antibody deficiency.

Within this market, immunoglobulin replacement therapy is expected to remain the largest segment as it helps to improve the immune system function and also reduces the risk of infections in primary immunodeficiency disorders patients.

North America will remain the largest segment due to high prevalence of primary immunodeficiency disorders and availability of reimbursement for primary immunodeficiency disorders therapeutics.

Features of the Global Primary Immunodeficiency Therapeutics Market

Market Size Estimates: Primary immunodeficiency therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Primary immunodeficiency therapeutics market size by type, disease type, and region in terms of value ($B).

Regional Analysis: Primary immunodeficiency therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, disease types, and regions for the primary immunodeficiency therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the primary immunodeficiency therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the primary immunodeficiency therapeutics market size?

Answer: The global primary immunodeficiency therapeutics market is expected to reach an estimated $11.1 billion by 2030.

Q.2 What is the growth forecast for primary immunodeficiency therapeutics market?

Answer: The global primary immunodeficiency therapeutics market is expected to grow with a CAGR of 6.3% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the primary immunodeficiency therapeutics market?

Answer: The major drivers for this market are increasing primary immunodeficiency disorders awareness, rising genomic research, and on-going advancement in diagnostoc technologies, such as genetic testing, flow cytometry, and next-generation sequencing.

Q4. What are the major segments for primary immunodeficiency therapeutics market?

Answer: The future of the primary immunodeficiency therapeutics market looks promising with opportunities in the immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, and gene therapy markets.

Q5. Who are the key primary immunodeficiency therapeutics market companies?

Answer: Some of the key primary immunodeficiency therapeutics companies are as follows:

  • Pfizer
  • CSL Behring
  • Grifols
  • Abbott
  • Adma Biologics
  • Astrazeneca
  • Baxter
  • Bayer
  • Biocon
  • Bristol-Myers Squibb

Q6. Which primary immunodeficiency therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that antibody deficiency will remain the largest segment due to increasing awareness of antibody deficiency and aging population is more susceptible to antibody deficiency.

Q7. In primary immunodeficiency therapeutics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment due to high prevalence of primary immunodeficiency disorders and availability of reimbursement for primary immunodeficiency disorders therapeutics.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the primary immunodeficiency therapeutics market by type (immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, gene therapy, and others), disease type (antibody deficiency, cellular immunodeficiency, innate immune disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by disease type or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Primary Immunodeficiency Therapeutics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Primary Immunodeficiency Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Primary Immunodeficiency Therapeutics Market by Type
    • 3.3.1: Immunoglobulin Replacement Therapy
    • 3.3.2: Stem Cell/Bone Marrow Transplantation
    • 3.3.3: Antibiotic Therapy
    • 3.3.4: Gene Therapy
    • 3.3.5: Others
  • 3.4: Global Primary Immunodeficiency Therapeutics Market by Disease Type
    • 3.4.1: Antibody Deficiency
    • 3.4.2: Cellular Immunodeficiency
    • 3.4.3: Innate Immune Disorders
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Primary Immunodeficiency Therapeutics Market by Region
  • 4.2: North American Primary Immunodeficiency Therapeutics Market
    • 4.2.2: North American Primary Immunodeficiency Therapeutics Market by Disease Type: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others
  • 4.3: European Primary Immunodeficiency Therapeutics Market
    • 4.3.1: European Primary Immunodeficiency Therapeutics Market by Type: Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, and Others
    • 4.3.2: European Primary Immunodeficiency Therapeutics Market by Disease Type: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others
  • 4.4: APAC Primary Immunodeficiency Therapeutics Market
    • 4.4.1: APAC Primary Immunodeficiency Therapeutics Market by Type: Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, and Others
    • 4.4.2: APAC Primary Immunodeficiency Therapeutics Market by Disease Type: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others
  • 4.5: ROW Primary Immunodeficiency Therapeutics Market
    • 4.5.1: ROW Primary Immunodeficiency Therapeutics Market by Type: Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, and Others
    • 4.5.2: ROW Primary Immunodeficiency Therapeutics Market by Disease Type: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Primary Immunodeficiency Therapeutics Market by Type
    • 6.1.2: Growth Opportunities for the Global Primary Immunodeficiency Therapeutics Market by Disease Type
    • 6.1.3: Growth Opportunities for the Global Primary Immunodeficiency Therapeutics Market by Region
  • 6.2: Emerging Trends in the Global Primary Immunodeficiency Therapeutics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Primary Immunodeficiency Therapeutics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Primary Immunodeficiency Therapeutics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: CSL Behring
  • 7.3: Grifols
  • 7.4: Abbott
  • 7.5: ADMA Biologics
  • 7.6: AstraZeneca
  • 7.7: Baxter
  • 7.8: Bayer
  • 7.9: Biocon
  • 7.10: Bristol-Myers Squibb